Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVALDI observational study of Valdoxan in major depression
ISRCTN49411996Phase 4Completed
- Sponsor
- Servier
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Servier. Primary endpoints: Change in depressive symptoms, Effect on circadian rhythm dysfunction and sleep and 4 more. Started Mar 2009; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN49411996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49411996.